Journal profile · Chemistry, Multidisciplinary
Acta Pharmacologica Sinica
ISSN 1671-4083 · eISSN 1745-7254 · Nature Publishing Group · PEOPLES R CHINA · Monthly · Founded 1980
Acta Pharmacologica Sinica: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 10; hybrid open access; APC about USD 4,390; median 138 days to acceptance (101 articles, last 24 months); community-reported acceptance: about 63.75%; 257 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
Acta Pharmacologica Sinica is published by Nature Publishing Group and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Autophagy in Disease and Therapy, Neuroscience and Neuropharmacology Research and Ion channel regulation and function, together about 19.1% of its articles. Its main subfields are Molecular Biology. (generated from OpenAlex topic counts and CAS ranking data)
The Acta Pharmacologica Sinica (APS) encourages submissions from all areas of pharmacology and the life sciences. Please go to Aims and scope page for more details.
From the journal's Aims & Scope
Research area (LetPub): Chemistry, Multidisciplinary
Main research topics OpenAlex counts of recent articles; shares are approximate
- Autophagy in Disease and TherapyMedicine6.4%
- Neuroscience and Neuropharmacology ResearchNeuroscience6.3%
- Ion channel regulation and functionBiochemistry, Genetics and Molecular Biology6.3%
- Receptor Mechanisms and SignalingBiochemistry, Genetics and Molecular Biology6%
- Neuroinflammation and Neurodegeneration MechanismsNeuroscience5.1%
- Traditional Chinese Medicine AnalysisMedicine4.4%
- Cell death mechanisms and regulationBiochemistry, Genetics and Molecular Biology4.2%
- Cardiac electrophysiology and arrhythmiasMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
| Minor | Chemistry, Multidisciplinary | Zone 2 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Chemistry, Multidisciplinary | Zone 1 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 1
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 1 |
| Minor | Pharmacology & Pharmacy | Zone 1 |
| Minor | Chemistry, Multidisciplinary | Zone 2 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Indexing the journal's website claims
MEDLINEEmbaseCASCAB AbstractsCurrent ContentsPublisher website
Other: Google Scholar, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS
As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 10LetPub ·
- Impact factor (publisher) 2025
- 10.4Publisher website ·
- 5-year impact factor (publisher) 2025
- 10.8Publisher website ·
- CiteScore 2026-06
- 17.7LetPub ·
- SJR 2026-06
- 2.69LetPub ·
- SNIP 2026-06
- 1.93LetPub ·
- h-index
- 78LetPub ·
- h-index
- 147OpenAlex ·
- i10-index
- 3,467OpenAlex ·
- 2-year mean citedness
- 8.13OpenAlex ·
- Self-citation rate
- 1.9%LetPub ·
- Share of gold OA articles
- 11.02%LetPub ·
Volume
- Articles per year
- 238LetPub ·
- Downloads per year (publisher) 2025
- 3,887,964Publisher website ·
Articles by year OpenAlex count · 4,760 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 235 | 158 | 147 |
| 2025 | 257 | 218 | 1,578 |
| 2024 | 232 | 232 | 4,158 |
| 2023 | 167 | 167 | 5,035 |
| 2022 | 202 | 202 | 7,692 |
| 2021 | 258 | 249 | 10,655 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
138 daysMedian, submission to acceptance · P25–P75 98 days – 170 days
- Acceptance to online
- median 35 days (101 articles)
- Submission to online
- median 174 days
- Sample
- 101 articles with submission and acceptance dates (535 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2 monthsLetPub ·
- Average acceptance (community reports)
- 63.75%LetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,390 / EUR 3,690 / GBP 2,890 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Nature Publishing Group
- Country or region
- PEOPLES R CHINA
- Language
- English
- Frequency
- Monthly
- Founded
- 1980
- ISSN
- 1671-4083
- Electronic ISSN
- 1745-7254
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
- Author guidelines ↗LetPub
- Special issues ↗Publisher website
FAQ
Frequently asked questions about Acta Pharmacologica Sinica
What CAS zone is Acta Pharmacologica Sinica in?
In the 2025 upgraded edition of the CAS Journal Ranking, Acta Pharmacologica Sinica is in Zone 2 of Medicine, and in Zone 1 of the minor category Pharmacology & Pharmacy / Chemistry, Multidisciplinary. In the 2026 Xinrui edition it is in Zone 1 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Acta Pharmacologica Sinica?
The latest impact factor listed by LetPub is 10; CiteScore 17.7, h-index 147.
How long does peer review take at Acta Pharmacologica Sinica?
Based on the dates recorded on 101 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 138 days (interquartile range 98–170 days); authors report an average review time of about 2 months; the community-reported acceptance is “about 63.75%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Acta Pharmacologica Sinica?
According to LetPub and DOAJ records, Acta Pharmacologica Sinica is indexed in SCIE and Scopus. The journal's website also lists MEDLINE, Embase, CAS, CAB Abstracts and Current Contents; that list has not been checked against each database.
Is Acta Pharmacologica Sinica open access, and what is the APC?
Acta Pharmacologica Sinica is a hybrid journal. For open-access publication: APC about USD 4,390.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .